



**HAL**  
open science

## Effects of intraoperative high versus low inspiratory oxygen fraction (FiO<sub>2</sub>) on patient's outcome: A systematic review of evidence from the last 20 years

Charlotte Fasquel, Olivier Huet, Yves Ozier, Christophe Quesnel, Marc Garnier

### ► To cite this version:

Charlotte Fasquel, Olivier Huet, Yves Ozier, Christophe Quesnel, Marc Garnier. Effects of intraoperative high versus low inspiratory oxygen fraction (FiO<sub>2</sub>) on patient's outcome: A systematic review of evidence from the last 20 years. *Anaesthesia Critical Care & Pain Medicine*, 2020, 39 (6), pp.847 - 858. 10.1016/j.accpm.2020.07.019 . hal-04414487

HAL Id: hal-04414487

<https://hal.science/hal-04414487v1>

Submitted on 24 Jan 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

## **Effects of intraoperative high versus low inspiratory oxygen fraction (FiO<sub>2</sub>) on patient's outcome: a systematic review of evidence from the last 20 years**

Charlotte Fasquel, MD<sup>1,2</sup>; Olivier Huet, MD, PhD<sup>2,3</sup>; Yves Ozier, MD, PhD<sup>2,3</sup>; Christophe Quesnel, MD, PhD<sup>1,4</sup>; and Marc Garnier, MD, PhD<sup>1,4</sup>

<sup>1</sup> APHP.6 Sorbonne Université, GRC 29, DMU DREAM, Service d'Anesthésie-Réanimation et Médecine Périopératoire, Hôpital Tenon – 75020 Paris - France

<sup>2</sup> Centre Hospitalier Régional Universitaire de Brest, Service d'Anesthésie-Réanimation et Médecine Périopératoire – 29200 Brest - France

<sup>3</sup> Faculté de médecine et de sciences de la santé de Brest – 29238 Brest - France

<sup>4</sup> Faculté de médecine Sorbonne Université – 75013 Paris - France

Corresponding author:

Dr Marc Garnier

marc.garnier@aphp.fr

Service d'Anesthésie-Réanimation et Médecine Périopératoire – Hôpital Tenon – 4 rue de la Chine – 75020 Paris, France

Declarations of interest: none.

External funding: none.

## ABSTRACT

Despite numerous studies, controversies about the best intraoperative  $\text{FiO}_2$  remain. In 2016, the WHO recommended that adult patients undergoing general anaesthesia should be ventilated intraoperatively with an 80%  $\text{FiO}_2$  to reduce surgical site infection (SSI). However, several data suggest that hyperoxia could have adverse effects. In order to determine the potential effect of  $\text{FiO}_2$  on SSI, we included in this systematic review 23 studies (among which 21 randomized controlled trials [RCT]) published between 1999 and 2020, comparing intraoperative high versus low  $\text{FiO}_2$ . Results were heterogeneous but the most recent studies on one hand, and the largest RCTs on the other hand, reported no difference on the incidence of SSI regarding to intraoperative  $\text{FiO}_2$  during general anaesthesia. There was also no difference in the incidence of SSI depending of intraoperative  $\text{FiO}_2$  in patients receiving regional anaesthesia. The review on secondary endpoints (respiratory and cardiovascular adverse events, postoperative nausea and vomiting, postoperative length-of-stay and mortality) also failed to support the use of high  $\text{FiO}_2$ . On the opposite, some data from follow-up analyses and registry studies suggested a possible negative effect of high intraoperative  $\text{FiO}_2$  on long-term outcomes. In conclusion, the systematic administration of a high intraoperative  $\text{FiO}_2$  in order to decrease SSI or improve other perioperative outcomes seems unjustified in the light of the evidence currently available in the literature.

**Key words:** inspired oxygen fraction,  $\text{FiO}_2$ , surgical site infection, intraoperative oxygen, respiratory complications, mortality.

## INTRODUCTION

Oxygen is certainly the most commonly prescribed medication in anaesthesia, whether during general or regional anaesthesia, and from induction to hours after the end of surgery. For years, intraoperative high inspiratory oxygen fractions ( $FiO_2$ ) have been used to prevent and treat hypoxemia caused by alveolar hypoventilation, decrease in functional residual capacity, second gas effect, atelectasis and ventilation-perfusion mismatch, which could occur during all phases of anaesthesia. The justification of high  $FiO_2$  also lays in the hope to prevent hypoxemia and hypoxia when critical events such as unplanned extubation, hypovolemic or haemorrhagic shock occur during the surgical procedure. In addition, oxygen therapy may have perioperative beneficial effects as it has been reported that supplemental intraoperative oxygen could reduce the risk of surgical site infection (SSI), notably by facilitating neutrophils bacterial killing [1–5]. Another potential benefit is the reduction of postoperative nausea and vomiting (PONV) [6,7]. The complete mechanism remains unknown. One hypothesis is that supplemental oxygen improves oxygen partial pressure in ischemic intestinal tissue during abdominal surgery and decrease the release of serotonin [8]. Then, in 2016, the WHO strongly recommended that “adult patients undergoing general anaesthesia with tracheal intubation for surgical procedures should receive an 80% fraction of inspired oxygen intraoperatively and, if feasible, in the immediate postoperative period for 2-6h to reduce the risk of SSI” [9]. Nevertheless, several concerns have been raised about these guidelines and the potential adverse events associated with high  $FiO_2$ . Moreover the poor quality of evidence of this recommendation has also been criticized [10–15].

Indeed, it is now acknowledged that oxygen cannot be considered as an inert component. Actually, the physiological and physiopathological roles of oxygen and, more generally of radical species, have been studied extensively in medicine. When oxygen is combined to a free electron, they form very unstable elements called “reactive oxygen species” (ROS). Initially, ROS have only been considered for their potential toxic effects as they induce oxidative reactions that may generate membrane, DNA or protein damages [16–18]. However, after Mc Cord and Fridovich's discovery of superoxide dismutase (SOD), it appeared that oxygen and ROS played a key part in cell signalling [19–21]. Thus, administration of intraoperative supplemental oxygen can be a double-edged sword. High  $FiO_2$  at induction or during general anaesthesia promotes absorptive atelectasis over a few minutes [22–26]. In pathologic state such as shock or ischemia-reperfusion, hyperoxia may increase ROS generation within

mitochondria and if the redox homeostasis balance is disturbed, a pro-oxidant state could lead to cell injury [27–29]. Clinical evidences are in line with experimental findings as ROS metabolism seems to be implicated in the deleterious effects of ischemia-reperfusion following resuscitation from cardiac arrest and myocardial infarction [30–32]. Moreover, it is now advocated that oxygen therapy should carefully be prescribed in acutely ill patients as morbidity, and maybe mortality, seem linked to the amount of oxygen delivered [33]. Actually, it has been reported that acutely ill patients treated with conservative oxygen therapy may have a better outcome than those treated with a liberal oxygen strategy [34–36]. Finally, systemic and coronary vasoconstriction induced by hyperoxia may increase cardiovascular morbidity in high-risk patients [37,38].

Thus, the question of how and when oxygen should be delivered remains unresolved. There are pro (prevention of hypoxemia and hypoxia, decrease in the risk of SSI and PONV) and con (respiratory adverse events, increase in potential harmful ROS production) arguments to administer intraoperative high  $\text{FiO}_2$ . Consequently, intraoperative administration of oxygen is very dependent on each practitioner and varies widely in clinical practice. This has been well illustrated in a study published in 2018 across 29 hospitals in the United Kingdom. The authors reported that intraoperative  $\text{FiO}_2$  ranged from 25 to 100%, with a median  $\text{FiO}_2$  of 50% regardless of patient's requirements. Arterial oxygen partial pressure ( $\text{PaO}_2$ ) was supra-physiological ( $> 100$  mmHg) in 89% of the 378 patients [39].

The aim of this study was to assess the benefit-risk ratio of the intraoperative administration of high  $\text{FiO}_2$  by performing a systematic review over the 20 last years.

## **MATERIALS AND METHODS**

This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [40]. The PRISMA checklist is available as a supplementary file.

### **1. Search strategy**

A search was conducted from January 1, 1999 to February, 1<sup>st</sup> 2020 in MEDLINE (PubMed), CENTRAL (Cochrane) and ClinicalTrials.gov databases. The last search was conducted on March, 1<sup>st</sup> 2020. There was no restriction on the type of the study. The following keywords were used: «perioperative», «intraoperative», «preoperative», «postoperative», «oxygen», «supplemental oxygen», «oxygenation», «oxygen therapy», «oxygen inhalation therapy», «hypoxia», «hyperoxia», «FiO<sub>2</sub>», «FiO(2)», «inspired oxygen fraction», «oxygen inhaled fraction», «oxygen concentration», «oxygen administration», «oxygen dosage», «anaesthesia», «adverse effects», «adverse events», «outcomes», «surgical site infection», «postoperative wound infection», «nausea and vomiting», «PONV» (postoperative nausea and vomiting), «atelectasis», «pulmonary complications», «respiratory complications», «lung function», «respiratory failure», «residual functional capacity», «acute myocardial infarction», «myocardial injury after non cardiac surgery», «MINS» (myocardial injury after non-cardiac surgery), «length of stay», «death», «mortality», «cancer». Booleans operators « and », « or » and « not » were applied. The PubMed « similar article » function was used to expand the search.

### **2. Study selection**

Two authors (C.F. and M.G.) independently screened the titles and abstracts retrieved from the search for potential eligibility. To be considered for analysis, publications had to be written in English or in French. When the title and abstract indicated potential eligibility, the full-text article was analysed. Editorials, letters to the editor, animal studies and paediatrics studies were excluded from the analysis. The references of the selected articles were also screened to complete the search. The PRISMA flow diagram of study selection is presented in **Figure 1**.

### **3. Outcomes**

According to the Grade of Recommendation, Assessment, Development and Evaluation (GRADE) methodology, a preliminary classification of outcomes has been made by 3 investigators (C.F, M.G and C.Q) before reviewing the evidence using a 1–9 numerical scale, in which outcomes rated from 1 to 3 were considered as “low importance outcomes,” from 4 to 6 as “important but not critical outcomes,” and from 7 to 9 as “critical outcomes” [41]. Consequently, the judgement criteria used in our literature review were rated as follows: main criterion = surgical site infection (importance 8); secondary criteria = mortality (importance 9), adverse respiratory events (importance 7), adverse cardiovascular events (importance 7), length of stay (importance 6) and incidence of PONV (importance 4).

#### **4. Data extraction and analysis**

For each study, a first reviewer extracted the following data: first author, year of publication, study location, type of study, population studied, type of surgery, primary and secondary outcomes selected, and main results. Potential confounding factors that may influence the selected outcomes (for example the perioperative use of antibiotics, the composition of the inspired gas mixture, etc.) were reported. A second reviewer checked independently the extracted data. In case of a discrepancy, a consensus decision was made between the two reviewers. Study sample size and the relevance of the research were considered at the level of each study. Then, the methodological quality of RCTs was rated with the Oxford quality scoring system [42]. The analysis was performed according to decreasing hierarchical prioritization of data from meta-analyses of randomised controlled trials (RCTs) or individual RCTs to observational studies.

## RESULTS

### **1. Surgical site infection**

#### **1.1 Characteristics of the included studies**

The main characteristics of the studies included in the literature review concerning the outcome “surgical site infection” are summarized in **Table 1**. Twenty-nine studies were first included. However, 6 RCTs by Schietroma *et al.* were excluded from the analysis [43–48] because of the retraction of 2 RCTs due to the falsification of the statistics [45,46] and of another RCT [43] for plagiarism and similarities of data with those previously published by another group. In addition, the validity of the 3 non-retracted RCTs [44,47,48] is also being questioned, notably because all 6 RCTs of this group reported important differences in SSI incidence systematically in favour of the high FiO<sub>2</sub> group. Eventually, 23 studies, among which 21 RCTs, were included in this review. Fifteen out of these 21 RCTs compared high versus low FiO<sub>2</sub> during surgery in patients under general anaesthesia (n=6984 patients); while the 6 remaining concerned patients receiving loco-regional anaesthesia (n=2184 patients). Their quality assessment is reported in **Figure 2**.

For surgeries performed under general anaesthesia, the main surgical procedure was abdominal surgery (exclusively for 12 and mixed with other surgeries for 2 out of the 15 RCTs; n=5715 patients operated from abdominal surgery/6984 patients operated under general anaesthesia). Among abdominal surgeries, major abdominal procedures represented the large majority of interventions (exclusively in 11 and mixed with minor surgeries in 3 out of the 14 RCTs including abdominal procedures; n= 5179 patients operated from major abdominal surgery/5715 patient operated from abdominal surgery). For surgeries performed under loco-regional anaesthesia, the surgical procedure was caesarean sections under epidural anaesthesia in the 6 RCTs.

Definitions of “SSI” used in the studies were the CDC definition (n=10/21 RCTs) [49], the ASEPSIS definition (Additional treatment, Serous discharge, Erythema, Purulent discharge, Separation of deep tissues, Isolation of bacteria, and prolonged Stay in hospital >14 days) (n=4/21 RCTs) [50], or other trial-specific definitions (n=7/21 RCTs). The evaluation of the occurrence of a SSI was performed at day 15 or 30 after surgery in most studies.

About the main confounding factors that may influence the incidence of SSI, the second gas (i.e. composing the gas mixture with oxygen) used was variable (nitrous oxide or nitrogen);



antibiotic prophylaxis was protocolized in all studies but the protocol was not always followed; mean body temperature was effectively maintained above 36°C in only 10/21 RCTs (temperature was lower or not specified in the other studies); the total amount of fluid administered during the surgery was protocolized in only 4/21 RCTs; and only one study specified whether non-steroidal anti-inflammatory drugs were prescribed postoperatively. Duration of a systematic post-operative oxygen therapy varied from 0 to 72 hours.

## **1.2 Results of the studies performed during general anaesthesia**

**1.2.1 RCTs.** Four RCTs reported a reduction in the incidence of SSI in the high FiO<sub>2</sub> group [51–54], 2 RCTs reported a reduction in the low FiO<sub>2</sub> group [55,56], and 9 RCTs reported no significant difference between the groups [57–65]. The 3 largest multicentre RCTs were the PROXI trial (n=1386; 2009) [61], the trial performed by Kurz *et al.* (n=555; 2015) [58], and the iPROVE-O<sub>2</sub> trial (n=717; 2020) [65]. There was no difference in the incidence of SSI between the 80% and 30% FiO<sub>2</sub> groups neither in the PROXI trial (CDC definition of SSI within the first 15 postoperative days, no nitrous oxide, antibiotic prophylaxis protocolized and systematic postoperative epidural analgesia: 19.1% vs. 20.1%; p=0.64), nor in the Kurz *et al.* study (CDC definition of SSI within the first 30 postoperative days, no nitrous oxide, antibiotic prophylaxis protocolized: 15.8% vs. 15.6%; p=1.0), nor in the iPROVE-O<sub>2</sub> study (CDC definition of SSI within the first 7 postoperative days, no nitrous oxide, antibiotic prophylaxis protocolized: 8.9% vs. 9.4%; p=0.90). The incidence of deep SSI was higher in the high FiO<sub>2</sub> group in Kurz study (7% vs. 3%; p=0.033).

Of note, the ENIGMA RCT by Myles *et al.* (n=2012; 2007) [52], that was included in most of the meta-analyses on this topic including the one that served to formalize the 2016 WHO recommendations [66], reported a reduction of SSI (secondary outcome) in the high vs. low FiO<sub>2</sub> group (7.7% vs. 10%; OR 0.72 95%CI [0.53-0.98]; p=0.034). However, the first aim of this study was to assess the effect of nitrous oxide avoidance, leading to a high FiO<sub>2</sub> group ventilated without N<sub>2</sub>O (80% O<sub>2</sub>/20% N<sub>2</sub>) and a low FiO<sub>2</sub> group ventilated with 70% N<sub>2</sub>O/30% O<sub>2</sub>.

**1.2.2 Non-randomized studies.** Kurz *et al.* performed a large cluster cross-over randomized trial in which the FiO<sub>2</sub> was set alternately at 30% and 80% biweekly for all the patients undergoing colorectal surgery [67]. From 2013 to 2016, 5749 patients were followed. The incidence of the composite primary endpoint (SSI, wound complication and 30-day surgical

mortality) was similar between the 2 groups (10.8% vs. 11% in the high and low FiO<sub>2</sub> groups, respectively; RR 0.99 [0.85-1.14]; p=0.85). There was also no between-group difference regarding the “SSI” outcome alone (4.1% vs. 3.9%; RR 1.04 [0.74-1.46]; p=0.77). Wanta *et al.* matched 1250 cases with 3248 controls who undergone abdominal, orthopaedic, vascular and neurosurgical surgeries, and found no association between increased oxygen exposure during surgery and the incidence of SSI in a multivariable logistic regression model [68].

### **1.3 Results of the studies performed during loco-regional anaesthesia**

Six RCTs compared the incidence of SSI when administering high or low FIO<sub>2</sub> during caesarean section. Three studies had used different oxygen delivery devices between the high (concentration mask) and low (nasal cannula) FiO<sub>2</sub> groups [69–71]. Only 2 studies specified the timing of antibiotic prophylaxis (at the time of cord clamping) [72,73]. The incidence of SSI varied from 1% [71] to 19% [72] depending on the studies. However, these 6 RCTs reported no significant difference between the high and low FiO<sub>2</sub> groups.

## **2. Secondary outcomes**

### **2.1 Adverse respiratory events**

The main characteristics of the studies included in the literature review concerning the outcome “adverse respiratory events” are summarized in the **Supplementary Table 1**. Eleven RCTs and 1 registry study were included.

#### **2.1.1 Atelectasis**

Of 9 RCTs, 6 reported no difference in the incidence of atelectasis [61,65,74–77]. Edmark *et al.* reported a significant but poorly relevant difference on the surface of atelectasis assessed by chest CT-scan performed just after the induction of anaesthesia between the 100% and 60% FiO<sub>2</sub> groups [25]. Similarly, Zoremba *et al.* reported fewer atelectasis in the 40% vs. 80% FiO<sub>2</sub> groups up to 24 hours after surgery in 142 overweight patients (BMI 25-35 kg/m<sup>2</sup>), without any difference in SaO<sub>2</sub> [78]. Finally, Myles *et al.* reported more atelectasis in the FiO<sub>2</sub> 30%/N<sub>2</sub>O 70% compared to the FiO<sub>2</sub> 80%/N<sub>2</sub> 20% group (13% vs. 7.5%; p<0.001) [52].

#### **2.1.2 Pneumonia**

Of 3 RCTs, only Myles *et al.* [52] reported an increased incidence of postoperative pneumonia in the 30% compared to the 80% FiO<sub>2</sub> groups (3% vs. 1.5%; p=0.031). Both Chen *et al.* (n=91) [57] and Staehr *et al.* (n=213 obese patients from the PROXI cohort) [77] reported a similar incidence of pneumonia between the 30% and 80% FiO<sub>2</sub> groups (9% vs. 3%, p=0.50 and 4.5% vs. 5.9%, p=0.65; respectively) after abdominal surgery.

### **2.1.3 Composite respiratory outcome**

In Myles study, the incidence of the composite respiratory outcome (pneumonia, atelectasis, pneumothorax and pulmonary embolism) was decreased in the FiO<sub>2</sub> 80%/N<sub>2</sub> 20% group compared to the FiO<sub>2</sub> 30%/N<sub>2</sub>O 70% group (7.8% vs. 13%; p<0.001) [52]. By contrast, Ferrando *et al.* reported in the most recent study in which lung-protective ventilation and an open-lung approach were used, no difference concerning the incidence of the composite respiratory outcome (13.1% vs. 15.2% in the 80% and 30% FiO<sub>2</sub> groups, respectively; p=0.50) [65]. Finally, Staehr-Rye *et al.* reported a dose-dependent association between the incidence of major respiratory complications (respiratory failure, reintubation, acute pulmonary oedema and pneumonia) and the increase in intra-operative median FiO<sub>2</sub> in a large prospective monocentric U.S. registry [79].

## **2.2 Adverse cardiovascular events**

The main characteristics of the studies included in the literature review concerning the outcome “adverse cardiovascular events” are summarized in the **Supplementary Table 2**. Three RCTs, the 5-year post-hoc follow-up study of the PROXI cohort and a registry study were included.

The 3 RCTs reported no difference in the incidence of myocardial infarction within 30 days after surgery [52,57,65]. At longer follow-up, the post-hoc analysis of the PROXI study [61] reported an increased incidence of myocardial infarction in the 80% compared to the 30% FiO<sub>2</sub> groups (2.2% vs. 0.9%; HR 2.86 [1.10-7.44]; p=0.03) at a median follow-up period of 3.9 years after surgery [80]. Finally, no association was reported between intra-operative FiO<sub>2</sub> and the incidence of postoperative myocardial infarction in the registry study by Staehr-Rye *et al.* [79].

## **2.3 Postoperative Nausea and Vomiting**

The main characteristics of the studies included in the literature review concerning the outcome “postoperative nausea and vomiting” are summarized in the **Supplementary Table 3**. Twelve RCTs (n=5656 patients) reported the incidence of PONV [6,7,52,63,81–87]. In great majority, the study population were women undergoing gynaecological, breast or abdominal surgery. Three RCTs reported a decreased incidence of PONV in the high FiO<sub>2</sub> group [6,7,52]. In the studies by Greif *et al.* (n=231; 1999) [6] and Goll *et al.* [7] (n=240; 2001), PONV incidence was halved in the 80% compared to the 30% FiO<sub>2</sub> group (17% vs. 30%; p=0.03 [6] - 22% vs. 44%; p=0.003 [7]). These two studies used inhaled anaesthesia with isoflurane, no intraoperative prevention of PONV and postoperative analgesia with piritramide without any loco-regional analgesia. Secondary outcomes such as time to oral re-feeding, hospital discharge, as well as patient satisfaction (measured by willingness to have the same anaesthesia for future surgery), were similar between groups. In the ENIGMA study, the incidence of PONV was lower in the N<sub>2</sub> 20%/O<sub>2</sub> 80% group compared to the N<sub>2</sub>O 70%/O<sub>2</sub> 30% group (10% vs. 23%; p<0.001 [52]). The other 9 RCTs (n=3173) did not report any difference in the incidence of PONV depending on intraoperative FiO<sub>2</sub> [61,63,81–87]. In particular, the studies by Joris *et al.* (n=150 thyroid surgeries, 2003) [81] and Turan *et al.* (n=559 mixed surgeries >1h, 2006) [85] designed with PONV incidence as primary outcome, reported similar incidence of nausea (46% vs. 48% and 26% vs. 20%, respectively) and vomiting (22% vs. 24% and 8% vs. 9%, respectively) in the high vs. low FiO<sub>2</sub> groups.

#### **2.4 Length-of-stay**

The main characteristics of the studies included in the literature review concerning the outcome “length-of-stay” are summarized in the **Supplementary Table 4**.

Nine RCTs and the Kurz cluster cross-over study reported the length-of-stay according to intraoperative FiO<sub>2</sub> [51–53,56,57,61,62,64,67,72]. Wasnik study reported a decreased length-of-stay in the high FiO<sub>2</sub> group (7.4±3.6 vs. 9.8±3.7 days; p=0.003) [64]. The main objective of this Indian monocentre study (n=64) was to compare intraoperative 80% vs. 30% FiO<sub>2</sub> on the incidence of SSI after appendicectomy. By contrast, the largest RCT having reported length-of-stay as a secondary outcome, the PROXI RCT (n=1386, abdominal surgery >2h) [61], reported similar length-of-stay in the 80% and 30% FiO<sub>2</sub> groups (6 (1-34) vs. 7 (2-36) days, respectively – p=0.09). The 7 other studies also reported no difference in length-of-stay between the high and low FiO<sub>2</sub> groups.

## 2.5 Mortality

The main characteristics of the studies included in the literature review concerning the outcome “mortality” are summarized in the **Supplementary Table 5**. Eight RCTs and 3 observational studies reported the mortality rate after general anaesthesia.

None of the 5 RCTs reporting short-term mortality reported any between-group difference [53,57,58,61,65]. In addition, Staehr-Rye *et al.* analysed 73,922 anaesthetic procedures for non-cardiothoracic surgeries from a monocentre U.S. registry [79] and reported that the median FiO<sub>2</sub> during anaesthesia was associated in a dose-dependent manner with increased mortality at day 7 and day 30. For instance, the OR for mortality at day 30 when comparing patients from the higher quintile of FiO<sub>2</sub> to those from the lower quintile was 1.97 [1.30-2.99] ( $p < 0.001$ ).

Accepted version

## DISCUSSION

The objective of our systematic review was to determine the benefit-risk balance of using high  $\text{FiO}_2$  in the operating room. Among the 23 studies (including 21 RCTs) comparing the effect of a high (80%) versus low (30%)  $\text{FiO}_2$  on the incidence of SSI, results were heterogeneous. However, the most recent studies reported no difference on the incidence of SSI with high or low  $\text{FiO}_2$  in patients undergoing general anaesthesia. The multicentre RCT PROXI published in 2009 [61], which was the second largest study ( $n=1386$ ) and had the best quality score (Oxford score 5/5), did not report any reduction of the incidence of SSI with the administration of 80%  $\text{FiO}_2$  during colorectal surgery. Similarly, the recent multicentre RCT iPROVE- $\text{O}_2$  reported a similar SSI rate between the 30% and 80%  $\text{FiO}_2$  groups [65]. Conversely, the large ENIGMA study ( $n=2012$ ) [52] reported opposite results. Further, this study was the only study among the 23 considered in the analysis that reported a significant benefit of a high  $\text{FiO}_2$  at the same time on the incidence of SSI, pneumonia, atelectasis, and postoperative nausea and vomiting. However, the main objective of this study was to evaluate the effects of nitrous oxide on the length-of-stay (primary outcome) and various secondary outcomes, such as SSI or respiratory complications, in patients undergoing major surgery. Therefore, randomization affected patients in a nitrous oxide-free group ( $\text{FiO}_2$  80%/ $\text{N}_2$  20%) or nitrous oxide group ( $\text{FiO}_2$  30%/ $\text{N}_2\text{O}$  70%), in which inspired oxygen fraction varied accordingly. Thus, it is not strictly speaking a comparison between high and low  $\text{FiO}_2$ , since one group received a high inspired fraction of nitrous oxide and the other group did not receive any. This is a major source of interpretation bias, especially considering that nitrous oxide may compromise host defence mechanisms [57], favour atelectasis, and contribute to nausea and vomiting [90].

The meta-analysis performed by de Jonge *et al.* on studies from 1990 to 2018 [91], reported a significant reduction of the incidence of SSI in the high intraoperative  $\text{FiO}_2$  group in intubated patients (RR 0.80 [0.64-0.99]). Clearly, the inclusion of Myles study in the analysis, whose sample of 2012 patients represented more than one third of the total population included in the meta-analysis (weight of 17% in the result of the analysis in ventilated patients), had impacted the overall effect. However, the level of evidence of the meta-analysis, as assessed by the authors themselves, was only moderate, and the results rather weak. Along these lines, our review, which included the two recent studies published beyond the inclusion period of de Jonge's meta-analysis [59,65], did not show a real benefit of high  $\text{FiO}_2$ . It should be recognized that the studies included in the meta-analysis by De Jonge and in our qualitative review,

presented significant heterogeneity, which should lead to cautious interpretation of the results. Indeed, some studies had small samples <100 patients [57,60,64] while others included more than 500 patients [52,53,58,61,65]. The incidence of SSI was also very different, from a few percent in some studies [57,63,67] to more than 20% others [51,59,61]. This may be due to the definition of SSI that was used in each study. Indeed, the way in which SSI is defined directly impacts its incidence. In a prospective observational study [92], the incidence of “SSI” ranged in the same cohort from 6.8% to 19% when using the ASEPIS score or the CDC definition to diagnose postoperative infection. In this context, it is questionable whether the comparison of results between studies not using the same SSI diagnostic criteria is relevant. The difference in incidence of SSI among the studies may also have been related to the different control of the confounding factors affecting the incidence of SSI, such as correct administration of antibiotic prophylaxis, perioperative maintenance of normothermia, etc. For instance, antibiotic prophylaxis was correctly administered to only 70% of the patients included in the large PROXI RCT [61]. Finally, the surgical site (abdominal vs. extra-abdominal) and the surgical approach (laparotomy or laparoscopy) were variable among studies, while this is known to impact the incidence of SSI [93].

Eventually, we believe that the available literature does not support the conclusion that there is a sufficiently significant effect of high  $\text{FiO}_2$  to recommend its systematic use to prevent SSI in patients who are mechanically ventilated in the operating room. This has been recently confirmed by the results of the large randomised iPROVE- $\text{O}_2$  trial, which used many of the current standards of perioperative management, at least in patients undergoing major abdominal surgery.

Considering patients operated under loco-regional anaesthesia, the results are more homogenous as the 6 available studies included caesarean sections and did not report any difference in the incidence of SSI between the high and low  $\text{FiO}_2$  groups. This is confirmed in the meta-analysis by de Jonge *et al.* [91] that included 5 of the 6 studies we identified in this review with the exception of Admadé’s study [70]. Thus, routine administration of supplemental oxygen to patients having caesarean section under epidural or spinal anaesthesia could be strongly questioned, considering that it does not appear to impact neither maternal nor foetal prognosis [94].

Considering secondary outcomes, the theoretical beneficial effect of a high FiO<sub>2</sub> is no more reported than for SSI prevention. No advantage on short-term mortality was reported in RCTs. However, demonstrating any potential effect of intraoperative FiO<sub>2</sub> on mortality would require a very large sample of patients, hardly compatible with the conduct of a RCT, as perioperative mortality has become very low. In this context, large registry studies can provide relevant arguments. Along these lines, the study by Staehr-Rye *et al.* [79] analysed data from 73,922 patients and reported a striking association between high FiO<sub>2</sub> and increased mortality at 7 and 30 days. This result has to be confirmed in further studies before concluding that there is a real noxious effect of high intraoperative FiO<sub>2</sub> on postoperative survival. Nevertheless, this result draws attention to the fact that the safety of high FiO<sub>2</sub> may not be as clear-cut as it sounds. Moreover, the follow-up study of the PROXI cohort showed higher 2-year mortality in patients randomized in the 80% compared to the 30% FiO<sub>2</sub> group (23.2% vs. 18.3% - p=0.03; and 33.5% vs. 24.6% for patients who undergone cancer surgeries - p=0.009) [88]. This highlights the need to extend the monitoring and analysis period to long-term mortality in future studies, notably in carcinologic patients.

Finally, the results on respiratory adverse events were inconclusive. Due to the age of some studies, the intraoperative ventilatory parameters used in these studies did not follow current recommendations on perioperative protective ventilation: tidal volumes up to 10 ml/kg, no use of PEEP, absence of alveolar recruitment manoeuvres, and use of nitrous oxide. In the light of the progress made in the field of perioperative ventilation, these results seem difficult to transpose into current practice. This seems particularly true when taking into account the increasing proportion of ambulatory surgery and the rapid implementation of enhanced recovery measures after surgery. To confirm these words, the recent iPROVE-O<sub>2</sub> trial, which used a mechanical ventilation strategy following the most recent guidelines based on protective ventilation and open-lung approach during the entire duration of anaesthesia, did not report any difference in atelectasis and pulmonary complication rates between the 80% and 30% FiO<sub>2</sub> groups.

In conclusion, the systematic administration of a high intraoperative FiO<sub>2</sub> in order to reduce surgical site infections seems unjustified in the light of the evidence currently available in the literature. While evidence of toxicity of a high FiO<sub>2</sub> remains to be demonstrated, there is no evidence that high FiO<sub>2</sub> can improve postoperative patient's outcome on its own.



Accepted version

Table 1. Summary of the main characteristics and results of the studies included and analyzed for the main outcome "SSI".

Study	Country	Design, n	Type of surgery, procedure duration	O <sub>2</sub> duration in recovery room	SSI definition, follow up	SSI, n (%)	Gas <sup>1</sup>	Antibiotic prophylaxis	Temp. <sup>2</sup>	Fluids	Analgesia
<b>Greif et al. [53], 2000</b>	Austria, Germany, USA	RCT Multicentre n=500	Colorectal, 3.1h	2h	Wound infection (pus), Day 15	FiO <sub>2</sub> 80%: 13/250 (5.2%) FiO <sub>2</sub> 30%: 28/250 (11.2 %) p=0.01	N <sub>2</sub>	No <sup>3</sup>	Yes	15ml/kg/h	NA/NP
<b>Pryor et al. [56], 2004</b>	USA	RCT Monocentre n=160	Major abdominal laparotomy or laparoscopy, 3.5h	2h	Clinical and paraclinical requiring medical support, Day 14	FiO <sub>2</sub> 80%: 20/80 (25%) FiO <sub>2</sub> 35%: 9/80 (11.3 %) p=0.02	N <sub>2</sub> O	Yes	No	15ml/kg/h	NA/NP
<b>Belda et al. [51], 2005</b>	Spain	RCT Multicentre n=291	Colorectal laparotomy	6h	CDC, Day 14	FiO <sub>2</sub> 80%: 22/148 (14.9%) FiO <sub>2</sub> 30%: 35/143 (24.4%) p=0.04	Air	Yes	Yes	15ml/kg/h	NSAID
<b>Mayzler et al. [60], 2005</b>	Israel	RCT Monocentre n=38	Colorectal Carcinologic, 2.3h	2h	Wound infection, Day 30	FiO <sub>2</sub> 80%: 2/19 (12.5%) FiO <sub>2</sub> 30%: 3/19 (17.6%) p=0.53	N <sub>2</sub> , N <sub>2</sub> O	Yes	NA/NP	15ml/kg/h	PCA
<b>Myles et al. [52] 2007</b>	Australia	RCT Multicentre n=2012	Major surgery > 2h <sup>i</sup> , 3.1h	-	Wound infection (pus or positive culture), Day 30	FiO <sub>2</sub> 80%: 77/997 (7.7%) FiO <sub>2</sub> 30%: 106/1015 (10.4%) p=0.034	N <sub>2</sub> , N <sub>2</sub> O	Yes	NA/NP	NA/NP	+/- Regional analgesia
<b>Gardella et al. [72], 2008</b>	USA	RCT Monocentre n=143	Caesarean section under regional anaesthesia, 0.8h	2h	Endometritis or wound infection requiring ATB, Day 14	Mask 15L/min: FiO <sub>2</sub> 80%: 17/69 (25%) FiO <sub>2</sub> 30%: 10/74 (14%) p=0.13	Air	Yes (at cord clamp)	NA/NP	NA/NP	NA/NP
<b>Meyhoff et al. [61], 2009</b>	Denmark	RCT Multicentre n=1386	Abdominal laparotomy, 2.2h	2h <sup>4</sup>	CDC, Day 14	FiO <sub>2</sub> 80%: 131/685 (19.1%) FiO <sub>2</sub> 30%: 141/701 (20.1%) p=0.64	Air	Yes (70% of cases)	Yes	Restrictive	Perimedullary block (70%)
<b>Anthony et al. [55], 2011</b>	USA	RCT Monocentre n=197	Colorectal laparotomy or laparoscopy, 2.7h	2h <sup>5</sup>	CDC, Day 30	FiO <sub>2</sub> 80%: 45/100 (45%) FiO <sub>2</sub> 30%: 23/97 (24%) p=0.003	NA/NP	Yes	Yes	NA/NP	NA/NP
<b>Bickel et al. [54], 2011</b>	Israel	RCT Monocentre n= 210	Appendectomy Mac Burney, 0.5h	2h	ASEPSIS, Day 14	FiO <sub>2</sub> 80%: 6/107 (5.6%) FiO <sub>2</sub> 30%: 14/103 (13.6%) p=0.04	N <sub>2</sub> , Air	Yes	Yes	NA/NP	NA/NP

<b>Scifres et al. [69], 2011</b>	USA	RCT Monocentre n=585	Caesarean section under regional anaesthesia, 1h	2h <sup>6</sup>	Endometritis or wound infection, Day 30	10L/min (FiO <sub>2</sub> 80%): 35/288 (12.2%) 2L/min (FiO <sub>2</sub> 30%): 26/297 (8.8%) p=0.18	Air	Yes	NA/NP	NA/NP	NA/NP
<b>Thibon et al. [63], 2012</b>	France	RCT Multicentre n=434	Abdominal laparoscopy/tomy + breast cancer surgery, 1.5h	-	CDC, Day 30	FiO <sub>2</sub> 80%: 15/226 (6.6%) FiO <sub>2</sub> 30%: 15/208 (7.2%) p=0.81	Air	Yes (51.5% of cases)	NA/NP	NA/NP	NA/NP
<b>Admadé et al. [70], 2013</b>	Panama	RCT Monocentre n=343	Caesarean section under regional anaesthesia, -	2h <sup>8</sup>	CDC Day 30	FiO <sub>2</sub> 80%: 9/164 (5.5%) AA: 13/179 (7.3%) p=0.33	Air	Yes	NA/NP	NA/NP	NA/NP
<b>Chen et al. [57], 2013</b>	Hong Kong	RCT Monocentre n=91	Colorectal, 2.8h	24h <sup>9</sup>	CDC, Day 30	FiO <sub>2</sub> 80% + N <sub>2</sub> : 2/30 (6.7%) FiO <sub>2</sub> 30% + N <sub>2</sub> O: 2/30 (6.7%) FiO <sub>2</sub> 30% + N <sub>2</sub> : 6/31 (9.4%) p=0.21	N <sub>2</sub> N <sub>2</sub> O	Yes	Yes	NA/NP	PCA Perimedullary block (15.5%)
<b>Duggal et al. [95], 2013</b>	USA	RCT Monocentre n=831	Caesarean section under regional anaesthesia -	1h	Endometritis or wound infection, Day 45	10L/min (FiO <sub>2</sub> 80%): 34/416 (8.2%) 10L/min (FiO <sub>2</sub> 30%): 34/415 (8.2%) p=0.89	Air	Yes	NA/NP	NA/NP	NA/NP
<b>Stall et al. [62], 2013</b>	USA	RCT Monocentre n=235	Orthopaedic trauma surgery <sup>10</sup> , 3.8h	2h	CDC, Day 84	FiO <sub>2</sub> 80%: 14/119 <sup>11</sup> (12%) FiO <sub>2</sub> 30%: 19/116 (16%) p=0.31	-	Yes	NA/NP	NA/NP	NA/NP
<b>Williams et al. [73], 2013</b>	USA	RCT Monocentre n=160	Caesarean section under regional anaesthesia 0.9h	2h	CDC, endometritis, Day 42	FiO <sub>2</sub> 80%: 10/77 (13.0%) FiO <sub>2</sub> 30%: 12/83 (14.5%) p=0.82	Air	Yes (at cord clamp)	NA/NP	NA/NP	NA/NP
<b>Kurz et al. [58], 2015</b>	USA, Ireland, Austria	RCT Multicentre n=555	Colectomy laparotomy > 2h, 3.5h	1h	CDC, Day 30	FiO <sub>2</sub> 80%: 45/285 (15.8%) FiO <sub>2</sub> 30%: 42/270 (15.6%) p=1.00	N <sub>2</sub>	Yes	Yes	NA/NP	Perimedullary block
<b>Wasnik et al. [64], 2015</b>	India	RCT Monocentre n=64	Appendectomy Mac Burney, 1h	2h <sup>13</sup>	ASEPSIS, Day 14	FiO <sub>2</sub> 80%: 0/32 FiO <sub>2</sub> 30%: 0/32	NA/NP	Yes	Yes	NA/NP	NA/NP
<b>Fariba et al. [71], 2016</b>	Iran	RCT Monocentre n=122	Caesarean section under regional anaesthesia, 1h	6h	ASEPSIS, Day 14	FiO <sub>2</sub> 80%: 0/61 FiO <sub>2</sub> 30%: 1/61 p>0.05	NA/NP	NA/NP	NA/NP	NA/NP	NA/NP

<b>Kurz et al. [67], 2018</b>	USA	Interventional <sup>14</sup> Monocentre n=5749	Major abdominal >2h laparotomy or laparoscopy		CDC, Day 30	FiO <sub>2</sub> 80%: 118/2896 (4.1%) FiO <sub>2</sub> 30%: 112/2853 (3.9%) p=0.77	NA/ NP	Yes	Yes	NA/NP	Perime- dullary (10%) TAP (3%)
<b>Wanta et al. [68], 2018</b>	USA	Case-control Monocentre 1250 cases 3248 controls over 10 years	General, orthopaedic, vascular, neurologic surgeries	-	CDC, Day 30	No association between duration with FiO <sub>2</sub> >50% (% of duration of the procedure) or nadir FIO <sub>2</sub> and SSI	NA/ NP	NA/NP	NA/NP	NA/NP	NA/NP
<b>Mayank et al. [59], 2019</b>	India	RCT Monocentre n=94	Colorectal	6h	ASEPSIS, Day 30	FiO <sub>2</sub> 80%: 26/47 (55.3%) FiO <sub>2</sub> 30%: 19/47 (40.4%) p=0.21	N <sub>2</sub>	NA/NP	NA/NP	NA/NP	NA/NP
<b>Ferrando et al. [65] 2020</b>	Spain	RCT Multicentre n=717	Abdominal >2h, 3.5h	3h	CDC Day 7 (main outcome) and day 30	FiO <sub>2</sub> 80%: 31/362 (8.9%) FiO <sub>2</sub> 30%: 34/355 (9.4%) p=0.90 FiO <sub>2</sub> 80%: 52/362 (16.5%) FiO <sub>2</sub> 30%: 62/355 (19.9%) p=0.89	Air	Yes (85% of cases)	NA/NP	NA/NP	Regional anaesthesia (44%)

O<sub>2</sub>: oxygen, SSI: surgical site infection, n: number, Temp.: temperature, N<sub>2</sub>: nitrogen, N<sub>2</sub>O: nitrous oxide, AA: ambient air NSAID: non-steroidal anti-inflammatory drug, CDC: Centers for Disease Control and Prevention, PCA: patient controlled analgesia, TAP: Transverse abdominal plane block, NA/NP: non available or non protocolized

<sup>1</sup> Carrier gas (air, N<sub>2</sub>O or N<sub>2</sub>).

<sup>2</sup> Mean body temperature at extubation ≥36°C.

<sup>3</sup> Empirical post-operative antibiotherapy.

<sup>4</sup> FiO<sub>2</sub> 80% : 14L/min, FiO<sub>2</sub> 30% : 2L/min.

<sup>5</sup> FiO<sub>2</sub> 80% group.

<sup>6</sup> FiO<sub>2</sub> 80%: 2L/min, FiO<sub>2</sub> 25-30%: 10L/min.

<sup>7</sup> Post-operative O<sub>2</sub> group: FiO<sub>2</sub> 30% at day 0 and day 1 then O<sub>2</sub> 5L/min until day 2.

<sup>8</sup> FiO<sub>2</sub> 80% group.

<sup>9</sup> FiO<sub>2</sub> 80% or 30%.

<sup>10</sup> Tibial plateau, tibial pilon, and calcaneus fractures.

<sup>11</sup> Fractures.

<sup>12</sup> During 16 hours post operatively.

<sup>13</sup> FiO<sub>2</sub> 80% group.

<sup>14</sup> FiO<sub>2</sub> was alternated between 30% and 80% at 2-week intervals for 39 months.

## Figure legends

**Figure 1:** Flow diagram of study selection for the assessment of the primary outcome (surgical site infection).

**Figure 2:** Oxford quality scoring system of the 23 RCTs included for the assessment of the primary outcome (surgical site infection).

Accepted version

## References

- [1] Niinikoski J, Jussila P, Vihersaari T. Radical mastectomy wound as a model for studies of human wound metabolism. *Am J Surg* 1973;126:53–8. [https://doi.org/10.1016/S0002-9610\(73\)80094-7](https://doi.org/10.1016/S0002-9610(73)80094-7).
- [2] Babior BM. Oxygen-Dependent Microbial Killing by Phagocytes. *N Engl J Med* 1978;298:659–68. <https://doi.org/10.1056/NEJM197803232981205>.
- [3] Knighton DR. Oxygen as an Antibiotic: The Effect of Inspired Oxygen on Infection. *Arch Surg* 1984;119:199. <https://doi.org/10.1001/archsurg.1984.01390140057010>.
- [4] Allen DB. Wound Hypoxia and Acidosis Limit Neutrophil Bacterial Killing Mechanisms. *Arch Surg* 1997;132:991. <https://doi.org/10.1001/archsurg.1997.01430330057009>.
- [5] Hopf HW. Wound Tissue Oxygen Tension Predicts the Risk of Wound Infection in Surgical Patients. *Arch Surg* 1997;132:997. <https://doi.org/10.1001/archsurg.1997.01430330063010>.
- [6] Greif R, Laciny S, Rapf B, Hickie RS, Sessler DI. Supplemental Oxygen Reduces the Incidence of Postoperative Nausea and Vomiting: *Anesthesiology* 1999;91:1246. <https://doi.org/10.1097/0000542-199911000-00014>.
- [7] Goll V, Akça O, Greif R, Freitag H, Arkiliç CF, Scheck T, et al. Ondansetron is no More Effective than Supplemental Intraoperative Oxygen for Prevention of Postoperative Nausea and Vomiting: *Anesth Analg* 2001;92:112–7. <https://doi.org/10.1097/0000539-200101000-00022>.
- [8] Pleuvry BJ. Physiology and pharmacology of nausea and vomiting. *Anaesth Intensive Care Med* 2006;7:473–7. <https://doi.org/10.1053/j.mpaic.2006.09.004>.
- [9] Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de Vries F, et al. New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. *Lancet Infect Dis* 2016;16:e288–303. [https://doi.org/10.1016/S1473-3099\(16\)30402-9](https://doi.org/10.1016/S1473-3099(16)30402-9).
- [10] Akca O, Ball L, Belda FJ, Biro P, Cortegiani A, Eden A, et al. WHO Needs High FIO2? *Turk J Anesth Reanim* 2017;45:181–92. <https://doi.org/10.5152/TJAR.2017.250701>.
- [11] Ball L, Lumb AB, Pelosi P. Intraoperative fraction of inspired oxygen: bringing back the focus on patient outcome. *Br J Anaesth* 2017;119:16–8. <https://doi.org/10.1093/bja/aex176>.
- [12] Hedenstierna G, Perchiazzi G, Meyhoff CS, Larsson A. Who Can Make Sense of the WHO Guidelines to Prevent Surgical Site Infection?: *Anesthesiology* 2017;126:771–3. <https://doi.org/10.1097/ALN.0000000000001604>.
- [13] Mellin-Olsen J, McDougall RJ, Cheng D. WHO Guidelines to prevent surgical site infections. *Lancet Infect Dis* 2017;17:260–1. [https://doi.org/10.1016/S1473-3099\(17\)30078-6](https://doi.org/10.1016/S1473-3099(17)30078-6).
- [14] Myles PS, Kurz A. Supplemental oxygen and surgical site infection: getting to the truth. *Br J Anaesth* 2017;119:13–5. <https://doi.org/10.1093/bja/aex096>.
- [15] Meyhoff CS. Perioperative hyperoxia: why guidelines, research and clinical practice collide. *Br J Anaesth* 2019;122:289–91. <https://doi.org/10.1016/j.bja.2018.12.016>.
- [16] Duranteau J, Chandel NS, Kulisz A, Shao Z, Schumacker PT. Intracellular Signaling by Reactive Oxygen Species during Hypoxia in Cardiomyocytes. *J Biol Chem* 1998;273:11619–24. <https://doi.org/10.1074/jbc.273.19.11619>.
- [17] Li J-M, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. *Am J Physiol-Regul Integr Comp Physiol* 2004;287:R1014–30. <https://doi.org/10.1152/ajpregu.00124.2004>.
- [18] Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. *Cell Metab* 2005;1:401–8. <https://doi.org/10.1016/j.cmet.2005.05.001>.
- [19] Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. *Am J Physiol-Cell Physiol* 2001;280:C719–41. <https://doi.org/10.1152/ajpcell.2001.280.4.C719>.

- [20] Kaminski KA, Bonda TA, Korecki J, Musial WJ. Oxidative stress and neutrophil activation—the two keystones of ischemia/reperfusion injury. *Int J Cardiol* 2002;86:41–59. [https://doi.org/10.1016/S0167-5273\(02\)00189-4](https://doi.org/10.1016/S0167-5273(02)00189-4).
- [21] Peters K. Molecular basis of endothelial dysfunction in sepsis. *Cardiovasc Res* 2003;60:49–57. [https://doi.org/10.1016/S0008-6363\(03\)00397-3](https://doi.org/10.1016/S0008-6363(03)00397-3).
- [22] Rothen HU, Sporre B, Engberg G, Wegenius G, Reber A, Hedenstierna G. Prevention of atelectasis during general anaesthesia. *The Lancet* 1995;345:1387–91. [https://doi.org/10.1016/S0140-6736\(95\)92595-3](https://doi.org/10.1016/S0140-6736(95)92595-3).
- [23] Rothen HU, Sporre B, Engberg G, Wegenius G, Hogman M, Hedenstierna G. Influence of Gas Composition on Recurrence of Atelectasis after a Reexpansion Maneuver during General Anesthesia: *Anesthesiology* 1995;82:832–42. <https://doi.org/10.1097/00000542-199504000-00004>.
- [24] Joyce CJ, Baker AB. Effects of inspired gas composition during anaesthesia for abdominal hysterectomy on postoperative lung volumes. *Br J Anaesth* 1995;75:417–21. <https://doi.org/10.1093/bja/75.4.417>.
- [25] Edmark L, Kostova-Aherdan K, Enlund M, Hedenstierna G. Optimal Oxygen Concentration during Induction of General Anesthesia: *Anesthesiology* 2003;98:28–33. <https://doi.org/10.1097/00000542-200301000-00008>.
- [26] Ladha K, Vidal Melo MF, McLean DJ, Wanderer JP, Grabitz SD, Kurth T, et al. Intraoperative protective mechanical ventilation and risk of postoperative respiratory complications: hospital based registry study. *BMJ* 2015:h3646. <https://doi.org/10.1136/bmj.h3646>.
- [27] Breen AP, Murphy JA. Reactions of oxyl radicals with DNA. *Free Radic Biol Med* 1995;18:1033–77.
- [28] Slater AFG, Stefan C, Nobel I, Orrenius S. The role of intracellular oxidants in apoptosis. *Biochim Biophys Acta BBA - Mol Basis Dis* 1995;1271:59–62. [https://doi.org/10.1016/0925-4439\(95\)00010-2](https://doi.org/10.1016/0925-4439(95)00010-2).
- [29] O'Reilly PJ, Hickman-Davis JM, Davis IC, Matalon S. Hyperoxia Impairs Antibacterial Function of Macrophages Through Effects on Actin. *Am J Respir Cell Mol Biol* 2003;28:443–50. <https://doi.org/10.1165/rcmb.2002-0153OC>.
- [30] Stub D, Smith K, Bernard S, Bray JE, Stephenson M, Cameron P, et al. A randomized controlled trial of oxygen therapy in acute myocardial infarction Air Verses Oxygen In myocardial infarction study (AVOID Study). *Am Heart J* 2012;163:339-345.e1. <https://doi.org/10.1016/j.ahj.2011.11.011>.
- [31] Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, et al. Oxygen Therapy in Suspected Acute Myocardial Infarction. *N Engl J Med* 2017;377:1240–9. <https://doi.org/10.1056/NEJMoa1706222>.
- [32] Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2018;39:119–77. <https://doi.org/10.1093/eurheartj/ehx393>.
- [33] Garnier M, Fasquel C, Salaün J-P, Quesnel C. Oxygen in critically ill patients: It is time to look at the other face of Janus. *Anaesth Crit Care Pain Med* 2019:S2352556819304849. <https://doi.org/10.1016/j.accpm.2019.12.002>.
- [34] Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, et al. Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial. *JAMA* 2016;316:1583. <https://doi.org/10.1001/jama.2016.11993>.
- [35] Chu DK, Kim LH-Y, Young PJ, Zamiri N, Almenawer SA, Jaeschke R, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. *The Lancet* 2018;391:1693–705. [https://doi.org/10.1016/S0140-6736\(18\)30479-3](https://doi.org/10.1016/S0140-6736(18)30479-3).
- [36] The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative Oxygen Therapy during Mechanical Ventilation in the ICU. *N Engl J Med* 2019:NEJMoa1903297. <https://doi.org/10.1056/NEJMoa1903297>.

- [37] Reinhart K, Bloos F, König F, Bredle D, Hannemann L. Reversible Decrease of Oxygen Consumption by Hyperoxia\*. *Chest* 1991;99:690–4. <https://doi.org/10.1378/chest.99.3.690>.
- [38] McNulty PH, King N, Scott S, Hartman G, McCann J, Kozak M, et al. Effects of supplemental oxygen administration on coronary blood flow in patients undergoing cardiac catheterization. *Am J Physiol-Heart Circ Physiol* 2005;288:H1057–62. <https://doi.org/10.1152/ajpheart.00625.2004>.
- [39] Pan London Perioperative Audit and Research Network (PLAN), Morkane CM, McKenna H, Cumpstey AF, Oldman AH, Grocott MPW, et al. Intraoperative oxygenation in adult patients undergoing surgery (iOPS): a retrospective observational study across 29 UK hospitals. *Perioper Med* 2018;7. <https://doi.org/10.1186/s13741-018-0098-3>.
- [40] Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 2009;6:e1000097. <https://doi.org/10.1371/journal.pmed.1000097>.
- [41] Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 2011;64:395–400. <https://doi.org/10.1016/j.jclinepi.2010.09.012>.
- [42] Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17:1–12.
- [43] Schietroma M, Carlei F, Cecilia EM, Piccione F, Bianchi Z, Amicucci G. Colorectal Infraperitoneal anastomosis: the effects of perioperative supplemental oxygen administration on the anastomotic dehiscence. *J Gastrointest Surg Off J Soc Surg Aliment Tract* 2012;16:427–34. <https://doi.org/10.1007/s11605-011-1717-1>.
- [44] Schietroma M, Cecilia EM, Carlei F, Sista F, De Santis G, Piccione F, et al. Prevention of anastomotic leakage after total gastrectomy with perioperative supplemental oxygen administration: a prospective randomized, double-blind, controlled, single-center trial. *Ann Surg Oncol* 2013;20:1584–90. <https://doi.org/10.1245/s10434-012-2714-7>.
- [45] Schietroma M, Cecilia EM, Sista F, Carlei F, Pessia B, Amicucci G. High-concentration supplemental perioperative oxygen and surgical site infection following elective colorectal surgery for rectal cancer: a prospective, randomized, double-blind, controlled, single-site trial. *Am J Surg* 2014;208:719–26. <https://doi.org/10.1016/j.amjsurg.2014.04.002>.
- [46] Schietroma M, Piccione F, Cecilia EM, Carlei F, De Santis G, Sista F, et al. RETRACTED: How does high-concentration supplemental perioperative oxygen influence surgical outcomes after thyroid surgery? A prospective, randomized, double-blind, controlled, monocentric trial. *J Am Coll Surg* 2015;220:921–33. <https://doi.org/10.1016/j.jamcollsurg.2015.01.046>.
- [47] Schietroma M, Cecilia EM, De Santis G, Carlei F, Pessia B, Amicucci G. Supplemental Peri-Operative Oxygen and Incision Site Infection after Surgery for Perforated Peptic Ulcer: A Randomized, Double-Blind Monocentric Trial. *Surg Infect* 2016;17:106–13. <https://doi.org/10.1089/sur.2013.132>.
- [48] Schietroma M, Pessia B, Colozzi S, Carlei F, Shehaj I, Amicucci G. Effect of High Perioperative Oxygen Fraction on Surgical Site Infection Following Surgery for Acute Sigmoid Diverticulitis. A Prospective, Randomized, Double Blind, Controlled, Monocentric Trial. *Chir Buchar Rom* 1990 2016;111:242–50.
- [49] Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol* 1999;20:250–78; quiz 279–80. <https://doi.org/10.1086/501620>.
- [50] Wilson APR, Sturridge MF, Treasure T, Grüneberg RN. A SCORING METHOD (ASEPSIS) FOR POSTOPERATIVE WOUND INFECTIONS FOR USE IN CLINICAL TRIALS OF ANTIBIOTIC PROPHYLAXIS. *The Lancet* 1986;327:311–2. [https://doi.org/10.1016/S0140-6736\(86\)90838-X](https://doi.org/10.1016/S0140-6736(86)90838-X).
- [51] Belda FJ. Supplemental Perioperative Oxygen and the Risk of Surgical Wound Infection A Randomized Controlled Trial. *JAMA* 2005;294:2035. <https://doi.org/10.1001/jama.294.16.2035>.
- [52] Myles PS, Leslie K, Chan MTV, Forbes A, Paech MJ, Peyton P, et al. Avoidance of Nitrous Oxide for Patients Undergoing Major Surgery: A Randomized Controlled Trial. *Anesthesiology* 2007;107:221–31. <https://doi.org/10.1097/01.anes.0000270723.30772.da>.



- [53] Greif R, Akça O, Horn E-P, Kurz A, Sessler DI. Supplemental Perioperative Oxygen to Reduce the Incidence of Surgical-Wound Infection. *N Engl J Med* 2000;342:161–7. <https://doi.org/10.1056/NEJM20001203420303>.
- [54] Bickel A. Perioperative Hyperoxygenation and Wound Site Infection Following Surgery for Acute Appendicitis: A Randomized, Prospective, Controlled Trial. *Arch Surg* 2011;146:464. <https://doi.org/10.1001/archsurg.2011.65>.
- [55] Anthony T. Evaluating an Evidence-Based Bundle for Preventing Surgical Site Infection: A Randomized Trial. *Arch Surg* 2011;146:263. <https://doi.org/10.1001/archsurg.2010.249>.
- [56] Pryor KO, Fahey III TJ, Lien CA, Goldstein PA. Surgical Site Infection and the Routine Use of Perioperative Hyperoxia in a General Surgical Population: A Randomized Controlled Trial. *JAMA* 2004;291:79. <https://doi.org/10.1001/jama.291.1.79>.
- [57] Chen Y, Liu X, Cheng CHK, Gin T, Leslie K, Myles P, et al. Leukocyte DNA Damage and Wound Infection after Nitrous Oxide Administration: A Randomized Controlled Trial. *Anesthesiology* 2013;118:1322–31. <https://doi.org/10.1097/ALN.0b013e31829107b8>.
- [58] Kurz A, Fleischmann E, Sessler DI, Buggy DJ, Apfel C, Akça O, et al. Effects of supplemental oxygen and dexamethasone on surgical site infection: a factorial randomized trial ‡. *Br J Anaesth* 2015;115:434–43. <https://doi.org/10.1093/bja/aev062>.
- [59] Mayank M, Mohsina S, Sureshkumar S, Kundra P, Kate V. Effect of Perioperative High Oxygen Concentration on Postoperative SSI in Elective Colorectal Surgery-A Randomized Controlled Trial. *J Gastrointest Surg Off J Soc Surg Aliment Tract* 2019;23:145–52. <https://doi.org/10.1007/s11605-018-3996-2>.
- [60] Mayzler O, Weksler N, Domchik S, Klein M, Mizrahi S, Gurman GM. Does supplemental perioperative oxygen administration reduce the incidence of wound infection in elective colorectal surgery? *Minerva Anesthesiol* 2005;71:21–5.
- [61] Meyhoff CS, Wetterslev J, Jorgensen LN, Henneberg SW, Høgdall C, Lundvall L, et al. Effect of High Perioperative Oxygen Fraction on Surgical Site Infection and Pulmonary Complications After Abdominal Surgery: The PROXI Randomized Clinical Trial. *JAMA* 2009;302:1543. <https://doi.org/10.1001/jama.2009.1452>.
- [62] Stall A, Paryavi E, Gupta R, Zadnik M, Hui E, O'Toole RV. Perioperative supplemental oxygen to reduce surgical site infection after open fixation of high-risk fractures: A randomized controlled pilot trial. *J Trauma Acute Care Surg* 2013;75:657–63. <https://doi.org/10.1097/TA.0b013e3182a1fe83>.
- [63] Thibon P, Borgey F, Boutreux S, Hanouz J-L, Le Coutour X, Parienti J-J. Effect of Perioperative Oxygen Supplementation on 30-day Surgical Site Infection Rate in Abdominal, Gynecologic, and Breast Surgery: The ISO2 Randomized Controlled Trial. *Anesthesiology* 2012;117:504–11. <https://doi.org/10.1097/ALN.0b013e3182632341>.
- [64] Wasnik N, Agrawal VP, Yede J, Gupta A, Soitkar S. Role of supplemental oxygen in reducing surgical site infection in acute appendicitis: Our experience of sixty four cases. *Int J Biomed Adv Res* 2015;6:124. <https://doi.org/10.7439/ijbar.v6i2.1654>.
- [65] Ferrando C, Aldecoa C, Unzueta C, Belda FJ, Librero J, Tusman G, et al. Effects of oxygen on post-surgical infections during an individualised perioperative open-lung ventilatory strategy: a randomised controlled trial. *Br J Anaesth* 2020;124:110–20. <https://doi.org/10.1016/j.bja.2019.10.009>.
- [66] WHO. WHO Surgical Site Infection Prevention Guidelines - Web Appendix 13 - Summary of systematic review on perioperative oxygenation 2016.
- [67] Kurz A, Kopyeva T, Suliman I, Podolyak A, You J, Lewis B, et al. Supplemental oxygen and surgical-site infections: an alternating intervention controlled trial. *Br J Anaesth* 2018;120:117–26. <https://doi.org/10.1016/j.bja.2017.11.003>.
- [68] Wanta BT, Hanson KT, Hyder JA, Stewart TM, Curry TB, Berbari EF, et al. Intra-Operative Inspired Fraction of Oxygen and the Risk of Surgical Site Infections in Patients with Type 1 Surgical Incisions. *Surg Infect* 2018;19:403–9. <https://doi.org/10.1089/sur.2017.246>.

- [69] Scifres CM, Leighton BL, Fogertey PJ, Macones GA, Stamilio DM. Supplemental oxygen for the prevention of postcesarean infectious morbidity: a randomized controlled trial. *Am J Obstet Gynecol* 2011;205:267.e1-267.e9. <https://doi.org/10.1016/j.ajog.2011.06.038>.
- [70] Admadé B, Reyes O. Supplemental Perioperative Oxygen (80% FIO<sub>2</sub>) for the Prevention of Surgical Site Infection after Emergency Cesarean Section. *ISRN Infect Dis* 2013;2013:1–4. <https://doi.org/10.5402/2013/526163>.
- [71] Fariba F, Loghman G, Daem R, Dina S, Jamal S. Effect of supplemental oxygen on the incidence and severity of Wound Infection after cesarean surgery. *J Chem Pharm Sci* 2016.
- [72] Gardella C, Goltra LB, Laschansky E, Drolette L, Magaret A, Chadwick HS, et al. High-Concentration Supplemental Perioperative Oxygen to Reduce the Incidence of Postcesarean Surgical Site Infection: A Randomized Controlled Trial. *Obstet Gynecol* 2008;112:545–52. <https://doi.org/10.1097/AOG.0b013e318182340c>.
- [73] Williams N, Glover M, Crisp C, Acton A, Mckenna D. Randomized Controlled Trial of the Effect of 30% versus 80% Fraction of Inspired Oxygen on Cesarean Delivery Surgical Site Infection. *Am J Perinatol* 2013;30:781–6. <https://doi.org/10.1055/s-0032-1333405>.
- [74] Akça O, Podolsky A, Eisenhuber E, Panzer O, Hetz H, Lampl K, et al. Comparable Postoperative Pulmonary Atelectasis in Patients Given 30% or 80% Oxygen during and 2 Hours after Colon Resection: *Anesthesiology* 1999;91:991. <https://doi.org/10.1097/0000542-199910000-00019>.
- [75] Kotani N, Hashimoto H, Sessler DI, Muraoka M, Hashiba E, Kubota T, et al. Supplemental Intraoperative Oxygen Augments Antimicrobial and Proinflammatory Responses of Alveolar Macrophages: *Anesthesiology* 2000;93:15–25. <https://doi.org/10.1097/0000542-200007000-00008>.
- [76] Staehr AK, Meyhoff CS, Henneberg SW, Christensen PL, Rasmussen LS. Influence of perioperative oxygen fraction on pulmonary function after abdominal surgery: a randomized controlled trial. *BMC Res Notes* 2012;5:383. <https://doi.org/10.1186/1756-0500-5-383>.
- [77] Stæhr AK, Meyhoff CS, Rasmussen LS. Inspiratory Oxygen Fraction and Postoperative Complications in Obese Patients: A Subgroup Analysis of the PROXI Trial. *Anesthesiology* 2011;114:1313–9. <https://doi.org/10.1097/ALN.0b013e31821bdb82>.
- [78] Zoremba M, Dette F, Hunecke T, Braunecker S, Wulf H. The influence of perioperative oxygen concentration on postoperative lung function in moderately obese adults: *Eur J Anaesthesiol* 2009;1. <https://doi.org/10.1097/EJA.0b013e32832e08c3>.
- [79] Staehr-Rye AK, Meyhoff CS, Scheffenbichler FT, Vidal Melo MF, Gätke MR, Walsh JL, et al. High intraoperative inspiratory oxygen fraction and risk of major respiratory complications. *Br J Anaesth* 2017;119:140–9. <https://doi.org/10.1093/bja/aex128>.
- [80] Fønnes S, Gögenur I, Søndergaard ES, Siersma VD, Jorgensen LN, Wetterslev J, et al. Perioperative hyperoxia — Long-term impact on cardiovascular complications after abdominal surgery, a post hoc analysis of the PROXI trial. *Int J Cardiol* 2016;215:238–43. <https://doi.org/10.1016/j.ijcard.2016.04.104>.
- [81] Joris JL, Poth NJ, Djamadar AM, Sessler DI, Hamoir EE, Defêchereux TR, et al. Supplemental oxygen does not reduce postoperative nausea and vomiting after thyroidectomy. *Br J Anaesth* 2003;91:857–61. <https://doi.org/10.1093/bja/aeg267>.
- [82] Purhonen S, Turunen M, Ruohoaho U-M, Niskanen M, Hynynen M. Supplemental Oxygen Does Not Reduce the Incidence of Postoperative Nausea and Vomiting After Ambulatory Gynecologic Laparoscopy: *Anesth Analg* 2003;96:91–6. <https://doi.org/10.1097/0000539-200301000-00020>.
- [83] Purhonen S, Niskanen M, Wüstefeld M, Hirvonen E, Hynynen M. Supplemental 80% oxygen does not attenuate post-operative nausea and vomiting after breast surgery: PONV: oxygen, ondansetron. *Acta Anaesthesiol Scand* 2006;50:26–31. <https://doi.org/10.1111/j.1399-6576.2005.00866.x>.
- [84] Bhatnagar S, Mishra S, Gupta M, Singhal A, Mandal A. Effects of different concentrations of intraoperative supplemental oxygen on post-operative nausea and vomiting (PONV) in patients under going modified radical mastectomy. *Internet J Anesth* 2005;9.
- [85] Turan A, Apfel CC, Kumpch M, Danzeisen O, Eberhart LHJ, Forst H, et al. Does the efficacy of supplemental oxygen for the prevention of postoperative nausea and vomiting depend on the

- measured outcome, observational period or site of surgery? *Anaesthesia* 2006;61:628–33. <https://doi.org/10.1111/j.1365-2044.2006.04703.x>.
- [86] McKeen DM, Arellano R, O'Connell C. Supplemental oxygen does not prevent postoperative nausea and vomiting after gynecological laparoscopy. *Can J Anesth Can Anesth* 2009;56:651–7. <https://doi.org/10.1007/s12630-009-9136-4>.
- [87] Šimurina T, Mraović B, Mikulandra S, Sonicki Z, Sulen N, Dukić B, et al. Effects of high intraoperative inspired oxygen on postoperative nausea and vomiting in gynecologic laparoscopic surgery. *J Clin Anesth* 2010;22:492–8. <https://doi.org/10.1016/j.jclinane.2009.10.013>.
- [88] Meyhoff CS, Jorgensen LN, Wetterslev J, Christensen KB, Rasmussen LS. Increased Long-Term Mortality After a High Perioperative Inspiratory Oxygen Fraction During Abdominal Surgery: Follow-Up of a Randomized Clinical Trial. *Anesth Analg* 2012;115:849–54. <https://doi.org/10.1213/ANE.0b013e3182652a51>.
- [89] Podolyak A, Sessler DI, Reiterer C, Fleischmann E, Akça O, Mascha EJ, et al. Perioperative Supplemental Oxygen Does Not Worsen Long-Term Mortality of Colorectal Surgery Patients. *Anesth Analg* 2016;122:1907–11. <https://doi.org/10.1213/ANE.0000000000001316>.
- [90] Sun R, Jia WQ, Zhang P, Yang K, Tian JH, Ma B, et al. Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia. *Cochrane Database Syst Rev* 2015:CD008984. <https://doi.org/10.1002/14651858.CD008984.pub2>.
- [91] de Jonge S, Egger M, Latif A, Loke YK, Berenholtz S, Boermeester M, et al. Effectiveness of 80% vs 30–35% fraction of inspired oxygen in patients undergoing surgery: an updated systematic review and meta-analysis. *Br J Anaesth* 2019;122:325–34. <https://doi.org/10.1016/j.bja.2018.11.024>.
- [92] Wilson APR, Gibbons C, Reeves BC, Hodgson B, Liu M, Plummer D, et al. Surgical wound infection as a performance indicator: agreement of common definitions of wound infection in 4773 patients. *BMJ* 2004;329:720. <https://doi.org/10.1136/bmj.38232.646227.DE>.
- [93] Ponz CB, Trias M. Laparoscopic Surgery and Surgical Infection. *J Chemother* 2001;13:17–22. <https://doi.org/10.1179/joc.2001.13.Supplement-2.17>.
- [94] Chatmongkolchart S, Prathep S. Supplemental oxygen for caesarean section during regional anaesthesia. *Cochrane Database Syst Rev* 2016. <https://doi.org/10.1002/14651858.CD006161.pub3>.
- [95] Duggal N, Poddatorri V, Noroozkhani S, Siddik-Ahmad RI, Caughey AB. Perioperative Oxygen Supplementation and Surgical Site Infection After Cesarean Delivery: A Randomized Trial. *Obstet Gynecol* 2013;122:79–84. <https://doi.org/10.1097/AOG.0b013e318297ec6c>.
-